找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Evidence-Based Psoriasis; Diagnosis and Treatm Tina Bhutani,Wilson Liao,Mio Nakamura Book 2018 Springer International Publishing AG, part o

[復(fù)制鏈接]
樓主: Dangle
21#
發(fā)表于 2025-3-25 05:51:28 | 只看該作者
22#
發(fā)表于 2025-3-25 09:24:59 | 只看該作者
23#
發(fā)表于 2025-3-25 13:17:34 | 只看該作者
Updates in Clinical Dermatologyhttp://image.papertrans.cn/e/image/317574.jpg
24#
發(fā)表于 2025-3-25 17:59:56 | 只看該作者
25#
發(fā)表于 2025-3-25 20:06:19 | 只看該作者
26#
發(fā)表于 2025-3-26 02:29:02 | 只看該作者
https://doi.org/10.1007/978-3-662-11675-3Currently, ultraviolet (UV)-based therapy is one of the first-line therapies for psoriasis due to its high response rate, relative low cost, and minimal generalized immunosuppression compared to other systemic therapies. This chapter will outline the basic principles of photomedicine and photochemis
27#
發(fā)表于 2025-3-26 05:36:37 | 只看該作者
Energie-Effizienzbewertung von Geb?udened to treat psoriasis include cytotoxic and immunomodulatory drugs such as methotrexate, cyclosporine, and apremilast. Another oral agent, acitretin, is a systemic retinoid that affects epidermal proliferation and differentiation as well as immunomodulation. Oral agents for psoriasis are effective a
28#
發(fā)表于 2025-3-26 12:14:03 | 只看該作者
29#
發(fā)表于 2025-3-26 14:54:45 | 只看該作者
Milton Burton,Günther O. Schenckcements have transformed treatment regimens for psoriasis by selectively targeting immune signaling molecules. The aim of this chapter is to review the clinical and research data surrounding these emerging treatments, ranging from those undergoing development to those already in clinical trials. The
30#
發(fā)表于 2025-3-26 18:00:45 | 只看該作者
Alexander Nikuradse,Hans J. Maderseverity of psoriasis. Using two or more therapies with varying mechanisms of action and safety profiles is often necessary to maintain adequate disease control while minimizing toxicity of treatments. Choosing a combination regimen that maximizes safety and efficacy, while at the same time consider
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 22:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
渭南市| 福建省| 临朐县| 六盘水市| 兴安盟| 余干县| 宣恩县| 金川县| 徐汇区| 洛川县| 遂平县| 山西省| 洛宁县| 丹凤县| 凉城县| 广昌县| 福海县| 陆川县| 竹北市| 新泰市| 隆德县| 松溪县| 阳春市| 台湾省| 鄂伦春自治旗| 莱阳市| 南京市| 浦东新区| 安溪县| 增城市| 永清县| 十堰市| 清镇市| 南川市| 德保县| 万年县| 淮安市| 缙云县| 迁西县| 博湖县| 丰原市|